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BACKGROUND
Observational evidence suggests that the use of a genotype-guided dosing algorithm 
may increase the effectiveness and safety of acenocoumarol and phenprocoumon 
therapy.
METHODS
We conducted two single-blind, randomized trials comparing a genotype-guided 
dosing algorithm that included clinical variables and genotyping for CYP2C9 and 
VKORC1 with a dosing algorithm that included only clinical variables, for the initia-
tion of acenocoumarol or phenprocoumon treatment in patients with atrial fibril-
lation or venous thromboembolism. The primary outcome was the percentage of 
time in the target range for the international normalized ratio (INR; target range, 
2.0 to 3.0) in the 12-week period after the initiation of therapy. Owing to low enroll-
ment, the two trials were combined for analysis. The primary outcome was assessed 
in patients who remained in the trial for at least 10 weeks.
RESULTS
A total of 548 patients were enrolled (273 patients in the genotype-guided group and 
275 in the control group). The follow-up was at least 10 weeks for 239 patients in the 
genotype-guided group and 245 in the control group. The percentage of time in the 
therapeutic INR range was 61.6% for patients receiving genotype-guided dosing and 
60.2% for those receiving clinically guided dosing (P = 0.52). There were no significant 
differences between the two groups for several secondary outcomes. The percentage of 
time in the therapeutic range during the first 4 weeks after the initiation of treatment 
in the two groups was 52.8% and 47.5% (P = 0.02), respectively. There were no signifi-
cant differences with respect to the incidence of bleeding or thromboembolic events.
CONCLUSIONS
Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve 
the percentage of time in the therapeutic INR range during the 12 weeks after the 
initiation of therapy. (Funded by the European Commission Seventh Framework 
Programme and others; EU-PACT ClinicalTrials.gov numbers, NCT01119261 and 
NCT01119274.)
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Coumarin anticoagulant agents such as acenocoumarol, phenprocoumon, and warfarin are frequently used for the 
prevention of stroke in patients with atrial fib-
rillation or for the treatment and prevention of 
 venous thromboembolism.1 In many countries, 
warfarin is used most frequently, but in some 
countries, acenocoumarol or phenprocoumon is 
prescribed.2 Coumarin anticoagulant drugs have 
a narrow therapeutic window, and there are large 
interpatient and intrapatient variations in the 
dose requirement. The anticoagulant effect of 
these drugs is monitored by means of regular 
measurement of the international normalized 
ratio (INR).3 A subtherapeutic INR is associated 
with an increased risk of stroke or thrombo-
embolism, whereas a supratherapeutic INR is 
associated with an increased risk of bleeding.4
Several factors influence the stability of the 
INR and the required coumarin dose. These fac-
tors include age, height, weight, sex, concomi-
tant medication use, and diet, but genetic factors 
also play an important role.5 Polymorphisms in 
two genes — VKORC1 (encoding the target en-
zyme of the drug, vitamin K epoxide reductase 
complex, subunit 1) and CYP2C9 (encoding the 
main metabolizing enzyme, cytochrome P-450, 
family 2, subfamily C, polypeptide 9) — together 
explain approximately one third of the variation 
in the dose requirement.6,7 Therefore, dosing al-
gorithms that use this genetic information may 
improve the prediction of the required coumarin 
dose and thereby increase the effectiveness and 
safety of the treatment.
The use of an algorithm that does not in-
clude genetic information but does include fac-
tors such as age, height, and weight may also 
improve the prediction of the required dose. 
Therefore, it is important to compare a dosing 
algorithm that includes genetic information 
with a dosing algorithm that does not include 
genetic information. This approach has been 
investigated in small or nonrandomized clini-
cal trials with warfarin,8,9 but it has not been 
studied with aceno coumarol or phenprocou-
mon. As part of the European Pharmacogenet-
ics of Oral Anticoagulant Therapy (EU-PACT) 
consortium, we investigated the effectiveness 
and safety of an algorithm including VKORC1 
and CYP2C9 genotypes and clinical factors, as 
compared with an algorithm including only 
clinical factors, for the initiation of dosing with 
acenocoumarol or phenprocoumon.10
ME THODS
STUDY DESIGN
The acenocoumarol and phenprocoumon com-
ponents of the EU-PACT study were originally 
designed as two separate multicenter, single-
blind, randomized, controlled trials. The aceno-
coumarol trial was conducted in the Netherlands 
and in Greece, and the phenprocoumon trial was 
conducted in the Netherlands. The two trials 
(one with acenocoumarol and the other with 
phenprocoumon) compared the effect of a geno-
type-guided dosing algorithm with the effect of 
a dosing algorithm based solely on clinical fac-
tors (control). The design of the two trials is de-
scribed in detail elsewhere.10 Because of low 
power resulting from low enrollment, the trials 
were combined for analysis.
The trials were designed by the members of 
the EU-PACT study group. Data were gathered by 
all the investigators and coinvestigators (for a 
full list, see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org) 
and were analyzed by the first author and a 
statistician who is an author, who vouch for the 
accuracy and completeness of the data reported. 
All the authors vouch for the adherence of the 
study to the protocols, which are available at 
NEJM.org. The first draft of the manuscript was 
written by the first author in close collaboration 
with the last author, with input from the other 
authors. The first two authors and the last two 
authors made the decision to submit the manu-
script for publication.
The Leiden Medical Ethics Committee ap-
proved the study protocols in the Netherlands, 
and the Scientific Council and Ethics Committee 
of the Academic General Hospital of Alexan-
droupolis and the institutional review board of 
the Onassis Cardiac Surgery Center approved the 
study protocol in Greece. An independent data 
and safety monitoring board periodically re-
viewed the efficacy and safety data. All medica-
tions were purchased. The trials were funded by 
the European Commission Seventh Framework 
Programme. LGC (former ly Laboratory of the Gov-
ernment Chemist) pro vided the point-of-care geno-
typing assay with funding from the European 
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Union. The funder and LGC had no role in the 
collection and interpretation of the data or in 
the writing of the manuscript or the decision to 
submit it for publication.
PATIENTS
Patients who had received a diagnosis of atrial 
fibrillation or venous thromboembolism and for 
whom at least 12 weeks of acenocoumarol or 
phenprocoumon treatment was planned were 
asked to participate in the trials. The trials en-
rolled only patients who had not received couma-
rin therapy previously. Detailed inclusion and 
exclusion criteria are provided in the Supplemen-
tary Appendix. All the patients provided written 
informed consent.
RANDOMIZATION AND TREATMENT
Patients were randomly assigned in a 1:1 ratio to 
either the genotype-guided group or the control 
group. Block randomization was performed accord-
ing to a computer-generated randomization list, 
with the use of a block size of 10, and was stratified 
according to study center and indication (atrial fi-
brillation or venous thromboembolism). Patients 
were unaware of the treatment assignment.
During the first 5 to 7 days of treatment (typi-
cally 6 days with 1 day of scheduling leeway), 
patients in the genotype-guided group were treated 
according to a dosing algorithm that included 
genotype information, and those in the control 
group were treated according to a dosing algo-
rithm that included only clinical information. 
After the first 5 to 7 days, patients were treated 
on the basis of the INR and in accordance with 
local clinical practice. Details about the genotyp-
ing and the specific dosing algorithms are pro-
vided in the Supplementary Appendix. Coumarin 
therapy was initiated on an outpatient basis in the 
Netherlands and on an inpatient basis in Greece.
FOLLOW-UP
The intended follow-up period for all patients 
was 12 weeks. Anticoagulation status was moni-
tored by means of INR measurement, before the 
daily dose of the coumarin anticoagulant was ad-
ministered, on days 1, 4, 6, 8, 15, 22, 57, and 85. 
The measurements planned on days 4 through 85 
could be adjusted slightly to coincide with week-
days. Additional INR measurements were carried 
out if clinically relevant. On the day of INR mea-
surement, the patients were also asked whether 
they had had any possible adverse events.
OUTCOME MEASURES
The primary outcome in both trials was the per-
centage of time in the therapeutic INR range (2.0 
to 3.0) during the 12 weeks after the initiation of 
coumarin therapy. In the Netherlands, the usual 
therapeutic INR range is 2.0 to 3.5, but patients 
included in the trial were all treated with a target 
range of 2.0 to 3.0. The percentage of time in the 
therapeutic range was calculated with the use 
of linear interpolation according to the method of 
Rosendaal et al.11
Secondary outcomes included the number of 
patients with an INR of 4.0 or more, the percent-
age of time with an INR of 4.0 or more or with 
an INR of less than 2.0, the time it took to reach 
a therapeutic INR, the time it took to achieve a 
stable dose, and the percentage of patients with 
a stable dose within 12 weeks. Additional sec-
ondary outcomes were the number of minor and 
major bleeding events, the number of thrombo-
embolic events, and the incidences of coumarin 
sensitivity and resistance. We also analyzed the 
percentage of time in the therapeutic range dur-
ing the first 4 weeks, during weeks 5 through 8, 
and during weeks 9 through 12 separately. Defi-
nitions of the outcomes are provided in the Sup-
plementary Appendix.
STATISTICAL ANALYSIS
We originally calculated that for each study to 
have 80% power to show a 5% improvement in 
the time in the therapeutic range with the geno-
type-guided dosing algorithm over the standard 
clinical algorithm, with a standard deviation of 
26.5% and at a 5% significance level, we would 
need to enroll 442 patients in each group. As-
suming a 10% withdrawal rate after study entry, 
we planned to include 986 patients in each study.
We performed a revised power calculation 
after new data became available from a trial 
conducted by Anderson et al.12 We increased the 
estimate of the expected improvement in the 
time in the therapeutic range (on the basis of 
data from Anderson et al.) and used a new esti-
mate of the expected standard deviation (derived 
from data collected in the EU-PACT trial up to the 
date of the revised power calculation). To detect 
a 7% improvement in the time in the therapeutic 
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range, with a standard deviation of 23%, a two-
sided significance level of 5%, and 80% power, we 
estimated that a sample of 200 patients in each 
group was necessary, assuming a withdrawal rate 
of 10%. As a consequence of low enrollment, the 
overall study coordinator and the national coordi-
nators in Greece and the Netherlands ultimately 
decided, before data unblinding, to conclude the 
two trials before the revised enrollment goal was 
reached and to combine the trials for analysis.
Only patients with at least 10 weeks of follow-
up were included in the analyses, with the excep-
tion of the time-to-event analyses and the separate 
analyses for the first 4 weeks and for weeks 5 
through 8. To increase the power and reduce the 
risk of bias, we performed a sensitivity analysis 
of the primary outcome that included data from 
patients with a follow-up of at least 2 weeks 
instead of 10 weeks. Per-protocol analyses were 
also performed.
Separate analyses were performed for aceno-
coumarol and phenprocoumon and for Greece and 
the Netherlands, followed by a pooled analysis 
of the acenocoumarol and phenprocoumon data. 
The primary outcome was calculated separately 
for both dosing-algorithm groups in the study, 
95% confidence intervals were constructed for the 
difference in the mean time in the therapeutic 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic Acenocoumarol Phenprocoumon Combined Acenocoumarol  and Phenprocoumon Data
Genotype-Guided 
Group
(N = 190)
Control  
Group
(N = 191)
Genotype-Guided 
Group
(N = 83)
Control 
Group
(N = 84)
Genotype-Guided 
Group
(N = 273)
Control  
Group
(N = 275)
Age — yr 68±14 68±13 67±11 67±11 68±13 68±13
Male sex — no. (%) 121 (64) 107 (56) 51 (61) 47 (56) 172 (63) 154 (56)
White race — no. (%)† 184 (97) 189 (99) 79 (95) 81 (96) 263 (96) 270 (98)
Atrial fibrillation — no. (%) 158 (83) 158 (83) 68 (82) 70 (83) 226 (83) 228 (83)
Height — cm 172±11 171±11 174±9 173±10 172±10 171±11
Weight — kg 84±15 82±18 87±17 83±16 85±16 82±17
CYP2C9 genotype — no. (%)
Data missing 0 4 (2%) 0 3 (4%) 0 7 (3%)
*1*1 111 (58) 107 (56) 55 (66) 57 (68) 166 (61) 164 (60)
*1*2 39 (21) 33 (17) 14 (17) 14 (17) 53 (19) 47 (17)
*1*3 29 (15) 32 (17) 11 (13) 7 (8) 40 (15) 39 (14)
*2*2 4 (2) 11 (6) 2 (2) 2 (2) 6 (2) 13 (5)
*2*3 5 (3) 4 (2) 1 (1) 1 (1) 6 (2) 5 (2)
*3*3 2 (1) 0 0 0 2 (1) 0
Hardy–Weinberg equilibrium for 
CYP2C9 genotype — P value
0.37 0.002 0.66 0.77 0.89 0.002
VKORC1 genotype — no. (%)
Data missing 0 4 (2) 0 3 (4) 0 7 (3)
GG 70 (37) 55 (29) 24 (29) 33 (39) 94 (34) 88 (32)
GA 84 (44) 93 (49) 40 (48) 33 (41) 124 (45) 126 (46)
AA 36 (19) 39 (20) 19 (23) 15 (18) 55 (20) 54 (20)
Hardy–Weinberg equilibrium for 
VKORC1 genotype — P value
0.23 0.97 0.77 0.20 0.23 0.47
Amiodarone use — no. (%) 22 (12) 23 (12) 0 0 22 (8) 23 (8)
* Plus–minus values are means ±SD. No significant differences with respect to baseline characteristics were found between the genotype-
guided and control groups.
† Race was self-reported.
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INR range, and a two-sample t-test was carried 
out to determine whether the difference was sig-
nificant. For the secondary outcomes, chi-square 
tests and time-to-event log-rank tests were used. 
A nominal two-sided P value of 0.05 was consid-
ered to indicate statistical significance.
R ESULT S
PATIENTS
A total of 1560 patients were assessed for eligi-
bility, and 548 were enrolled in the two trials 
(381 patients treated with acenocoumarol and 
167 treated with phenprocoumon). Of these, 
273 patients were assigned to the genotype-guided 
group and 275 to the control group. Patient en-
rollment and treatment assignments are shown 
in Figure S1 in the Supplementary Appendix.
The modified intention-to-treat population in-
cluded 484 patients, which excluded 64 patients 
who did not have at least 10 weeks of the intended 
12 weeks of follow-up. An additional 140 pa tients 
were excluded from the per-protocol analysis for 
the reasons outlined in Table S1 in the Supple-
mentary Appendix. The baseline characteristics of 
the patients in the two dosing- algorithm groups 
were similar (Table 1, and Table S2 in the Sup-
plementary Appendix).
PRIMARY OUTCOME
Among patients treated with acenocoumarol, the 
percentage of time in the therapeutic INR range 
during the 12-week study period was 62.3% in 
the genotype-guided group and 61.4% in the con-
trol group (difference [genotype-guided group 
minus control group], 0.9 percentage points; 
95% confidence interval [CI], −4.3 to 6.1; P = 0.74); 
among patients treated with phenpro coumon, the 
corresponding percentages of time were 60.1% and 
57.6% (difference, 2.5 percentage points; 95% CI, 
−4.5 to 9.4; P = 0.49) (Table 2). When all the data 
were pooled, the time in the therapeutic range 
was 61.6% in the genotype-guided group and 
60.2% in the control group (difference, 1.4 per-
centage points; 95% CI, −2.8 to 5.5; P = 0.52). The 
sensitivity analysis that included data from all 
patients with a follow-up of at least 2 weeks 
yielded similar results (Table S3 in the Supple-
mentary Appendix). The mean INR over time is 
shown for the two dosing-algorithm groups in 
Figure 1A, and the time in the therapeutic range is 
shown for these groups in Figure 1B.
SECONDARY OUTCOMES
Most of the secondary outcomes did not differ 
significantly between the two dosing-algorithm 
groups (Table 3). The time in the therapeutic 
range during the first 4 weeks after the initiation 
of treatment was higher among patients in the 
genotype-guided group, and this difference was 
significant in the combined analysis of aceno-
coumarol and phenprocoumon (52.8% vs. 47.5%; 
P = 0.02). Figure 2 shows the time it took to reach 
a therapeutic INR and the time it took to achieve 
a stable dose in the two dosing-algorithm groups. 
Secondary outcomes according to country are 
Table 2. Percentage of Time in the Therapeutic Range for the International Normalized Ratio (INR) during 12 Weeks 
after the Initiation of Treatment.*
Coumarin Group
Genotype-Guided 
Group
(N = 239)
Control  
Group
(N = 245)
Difference
(95% CI)† P Value
percent of time in therapeutic INR range percentage points
Acenocoumarol
Greece 62.6±26.7 64.1±23.8 –1.5 (–9.3 to 6.2) 0.70
The Netherlands 62.0±21.9 58.6±22.3 3.4 (–3.5 to 10.3) 0.33
Combined study sites 62.3±24.4 61.4±23.2 0.9 (–4.3 to 6.1) 0.74
Phenprocoumon 60.1±21.1 57.6±23.3 2.5 (–4.5 to 9.4) 0.49
Combined acenocoumarol and 
phenprocoumon data
61.6±23.3 60.2±23.2 1.4 (–2.8 to 5.5) 0.52
* Plus–minus values are means ±SD. The phenprocoumon trial was conducted only in the Netherlands. CI denotes confi-
dence interval.
† The between-group difference was calculated as the genotype-guided group minus the control group.
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shown in Table S4 in the Supplementary Appen-
dix. A per-protocol analysis of the data yielded 
similar results (Tables S5 through S8 in the Sup-
plementary Appendix).
The incidence of adverse events did not differ 
significantly between the two dosing-algorithm 
groups (Table 3, and Table S9 in the Supple-
mentary Appendix). There was only one major 
bleeding episode, which occurred in the control 
group. Thromboembolic events occurred in five 
patients in the genotype-guided group and in 
four in the control group.
DISCUSSION
In the EU-PACT trials, we investigated the use of 
a dosing algorithm that included both pharma-
cogenetic and clinical factors, as compared with 
an algorithm that included only clinical factors, 
for the initiation of treatment with acenocouma-
rol or phenprocoumon. There was no significant 
difference between the two groups in the pri-
mary outcome of time in the therapeutic INR 
range during the first 12 weeks of treatment. 
There were also no significant differences in most 
of the secondary outcomes, including the per-
centage of patients with an INR of 4.0 or more, 
the percentage of time with an INR of 4.0 or more 
or an INR of less than 2.0, the median time it 
took to reach a therapeutic INR, and the percent-
age of patients with a stable dose within 12 weeks.
We found a significant between-group differ-
ence in the time in the therapeutic range during 
the first 4 weeks of treatment. This observation 
must be interpreted cautiously. The division of 
the 12-week study into three 4-week intervals 
was not prespecified in the trial protocol, and it 
is only one of several secondary outcome mea-
sures. Because the P values in our study were not 
corrected for multiple testing, it is possible that 
the significant difference detected in the first 
4 weeks is a chance finding.
However, it is biologically plausible that the 
benefit of pharmacogenetically guided dosing, if 
there is one, would be most likely to occur dur-
ing the initiation of treatment. The trial algo-
rithms were used to determine drug doses only 
during the first 5 to 7 days of treatment. There-
after, in both groups, adjustments were based on 
the INR. The fact that we found an effect only in 
the first month of treatment is consistent with 
previous observational studies in which we found 
differences in over- and under-anticoagulation 
(i.e., supratherapeutic and subtherapeutic INRs) 
between the genotypes only in the first month.13,14
Anderson et al. found a significant difference 
in the percentage of time in the therapeutic INR 
range in the first month as well as in the first 
3 months of warfarin treatment.12 Their study was 
a nonrandomized comparison with a parallel con-
trol group in which standard anticoagulation 
therapy was provided without a dosing algo-
rithm. In our study, the patients in the control 
group received a dose that was based on a clini-
cal algorithm, which was also expected to im-
prove the time within the therapeutic range. In 
a smaller, randomized, controlled trial con-
ducted by Burmester et al., no significant differ-
ence in the time in the therapeutic range during 
the first 14 days was shown between pharmaco-
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Figure 1. Mean International Normalized Ratio (INR) and Time in the 
 Therapeutic Range.
Panel A shows the difference in the mean INR between the genotype-guided 
group and the control group, and Panel B the percentage of time within the 
therapeutic INR range during the 12-week follow-up period. Data were included 
for all patients with at least 2 weeks of follow-up.
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Table 3. Secondary and Safety Outcomes.
Outcome Acenocoumarol Phenprocoumon Combined Acenocoumarol  and Phenprocoumon Data
Genotype-
Guided 
Group
(N = 160)
Control 
Group
(N = 165) P Value
Genotype-
Guided 
Group
(N = 79)
Control 
Group
(N = 80) P Value
Genotype-
Guided 
Group
(N = 239)
Control 
Group
(N = 245) P Value
Secondary outcomes
Percentage of time in 
therapeutic INR 
range
Wk 1–4 54.5 50.4 0.15 49.0 41.2 0.05 52.8 47.5 0.02
Wk 5–8 66.0 62.8 0.40 61.6 60.1 0.92 64.6 62.2 0.44
Wk 9–12 66.0 70.9 0.21 69.5 69.8 0.95 67.1 70.6 0.28
Patients with INR ≥4.0 (%) 33.1 33.3 0.97 26.6 32.5 0.41 31.0 33.1 0.62
Percentage of time with 
INR ≥4.0
2.8 2.7 0.90 2.0 3.7 0.09 2.5 3.0 0.44
Percentage of time with 
INR <2.0
22.4 19.8 0.26 16.8 18.2 0.60 20.5 19.3 0.49
Time to reach therapeutic 
INR (days)
Median 22 22 0.76 22 23 0.07 22 22 0.53
95% CI 19–25 18–26 16–28 17–29 19–25 19–25
Patients with stable dose 
within 12 wk (%)*
43.8 49.1 0.33 62.0 61.2 0.92 49.8 53.1 0.47
Patients with coumarin 
sensitivity (%)†
2.9 5.2 0.39 5.0 8.9 0.40 3.7 6.4 0.25
Patients with coumarin 
resistance (%)‡
0 0 — 0 0 — 0 0 —
Mean no. of INR 
measurements
10.6 10.7 0.65 12.5 12.6 0.86 11.2 11.3 0.68
Mean absolute difference  
between calculated 
and achieved stable 
doses — mg/day§
0.5 0.6 0.06 0.4 0.6 0.15 22 31 0.04
Safety outcomes
No. of adverse events per 
person-mo
1.29 0.97 0.18 1.22 1.05 0.27 1.27 1.00 0.11
No. of serious adverse 
events per  
person-mo
0.07 0.06 0.78 0.13 0.02 0.16 0.09 0.05 0.25
No. of bleeding events per 
person-mo
0.39 0.39 0.89 0.34 0.38 0.57 0.38 0.38 0.94
No. of thromboembolic 
events per  
person-mo
0.02 0.02 0.80 0.01 0.00 0.18 0.02 0.01 0.62
* Too few patients in each group had a stable dose by the end of 12 weeks to allow for the calculation of the median time to a stable dose.
† Coumarin sensitivity was documented when the dose that was needed to achieve a stable dose in the therapeutic range was 1.0 mg or less 
for acenocoumarol or 1.5 mg or less for phenprocoumon.
‡ Coumarin resistance was documented when the dose that was needed to achieve a stable dose in the therapeutic range was 8 mg or more 
for acenocoumarol or 6 mg or more for phenprocoumon.
§ The calculated dose was determined by means of the dosing algorithm, and the achieved stable dose was the stable dose achieved during 
the trial. The difference was considered to be absolute because the value does not indicate whether the change was an increase or decrease. 
In the combined coumarin groups, the difference was calculated as a percentage of the achieved stable dose.
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genetically guided dosing and dosing based on a 
clinical algorithm.9 Wang et al. found that the 
time to a stable warfarin dose was decreased in 
the group that received genotype-guided dos-
ing.15 We did not observe this difference in our 
study. Wang and colleagues used a less strict 
definition of a stable dose (i.e., the dose at 
which the INR was in the range of 1.8 to 3.0 for 
at least 7 days) than we did, and therefore the 
time it took to reach a stable dose was longer in 
our study than in the study by Wang et al.
One important difference between all these 
previous studies and the current one is that the 
previous studies all evaluated pharmacogene-
tically guided dosing of warfarin rather than 
acenocoumarol or phenprocoumon. The CYP2C9 
enzyme has much less influence on the pharma-
cokinetics of phenprocoumon than on the phar-
macokinetics of warfarin.16 Thus, the effect on 
the determination of the appropriate dose and 
dose stability during therapy may be smaller 
with phenprocoumon than with warfarin, and 
the effect of the pharmacogenetically guided 
dosing on the time spent in the therapeutic INR 
range would also be expected to be less.
One limitation of our trial is the fact that the 
number of patients included was lower than the 
number required according to our power calcu-
lation. We were able to meet the requirements of 
our revised sample-size calculation only by pool-
ing the data from the acenocoumarol and phen-
procoumon groups. Another limitation was the 
high number of protocol violations, including in-
correctly calculated doses, doses not prescribed 
according to the protocol, and missing data for 
dose calculations. However, these issues would 
also arise if genotyping were implemented in 
clinical practice.
The percentage of time spent in, below, and 
above the target INR range is a surrogate out-
come used to investigate the quality of anti-
coagulation. For clinical practice, it is important 
to determine whether clinical outcomes such as 
bleeding and thromboembolic events are de-
creased when genotyping is used. Our study was 
not powered to detect clinically relevant differ-
ences with respect to these events. However, the 
risks of bleeding and thromboembolic events 
are lowest when the INR is within the target 
range.17 It is therefore plausible that an interven-
tion that increases the percentage of time in the 
target range will be associated with a decreased 
risk of adverse events.
In conclusion, we investigated the use of a 
dosing algorithm that included both pharmaco-
genetic and clinical factors, as compared with 
an algorithm that included only clinical factors, 
for the initiation of treatment with acenocouma-
rol or phenprocoumon. There was no significant 
difference between the two dosing-algorithm 
groups in the primary outcome of time in the 
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Figure 2. Kaplan–Meier Estimates of the Time to Reach a Therapeutic INR 
and the Time to Reach a Stable Dose.
Vertical lines indicate the censoring of data due to the occurrence of an 
event or loss to follow-up.
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therapeutic INR range during the first 12 weeks 
of treatment.
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